Abstract: Compounds that affect quorum sensing (QS) in Staphylococcus aureus and related Staphylococcus species (e.g., S. epidermidis). Compounds which modulate one or more of the four AgrC receptors of Staphylococcus species, particularly of Staphylococcus aureus. Modulation includes inhibition or activation of one or more of these four AgrC receptors. These compounds are useful for bacterial interference and are useful for treating bacterial infections, particularly staphylococcal infection. Treatment can include combination of one or more of the compounds of the invention in combination with one or more antibiotics.

Abstract: The invention relates to peptides that form adhesive bonds, even in aqueous and/or saline environments. When aggregated, the peptides may be used in methods for producing hydrogels and/or adhesive materials. Synthetic peptide analogs are provided that are designed based on protein sequences found in barnacle adhesive, and may optionally be augmented with chemistry from other organisms that secrete proteins that adhere to substrates. The peptides may be used, for example, in biomedical and aqueous applications. Methods of using the aggregated peptides as adhesives are also provided.

Abstract: Provided herein are compositions and methods for retargeting recombinant viral capsid proteins/capsids/vectors, e.g., in vivo, with a multispecific binding molecule, such as a bispecific antibody, that specifically binds a heterologous epitope displayed by the capsid protein and a protein expressed on the cell of interest for the targeted delivery of a nucleotide of interest.

Abstract: Provided herein are compositions and methods for redirecting recombinant viral capsid particles via a specific protein:protein binding pair that forms an covalent, e.g., isopeptide, bond to display a targeting ligand on the capsid protein, wherein the targeting ligand specifically binds a cell surface marker expressed on the cell of interest.

Abstract: Disclosed herein are modified capsid proteins comprising a capsid forming protein, a membrane binding element and an ESCRT-recruiting element, wherein at least one of the membrane binding element and the ESCRT-recruiting element is heterologous to the capsid forming protein. Disclosed are capsids comprising a plurality of modified capsid proteins. Disclosed are multimeric assemblies comprising a plurality of capsids within a membrane. Also disclosed are modified non-enveloped viruses comprising a capsid wherein the capsid comprises a plurality of modified capsid proteins, wherein the plurality of modified capsid proteins comprise a capsid forming protein, a membrane binding element and an ESCRT-recruiting element, wherein at least one of the membrane binding element and the ESCRT-recruiting element is heterologous to the modified capsid protein, wherein the capsid forming protein is a capsid forming protein of a non-enveloped virus.

Abstract: The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. The invention provides methods and compositions for stimulating an immune response against the bacteria. In certain embodiments, the methods and compositions involve a non-toxigenic Protein A (SpA) variant.

Abstract: The present invention relates to polypeptides having trehalase activity, particularly derived from Talaromyces. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides for the production of ethanol.

Abstract: A method for preparing a liquid extract rich in phycocyanin from cyanobacteria or microalgae containing phycocyanin in solution, comprising a step of carrying out the cellular lysis of an aqueous suspension of said fresh cyanobacteria or microalgae, a step of macerating the lysate obtained, for several hours in a solution of divalent cations, while releasing the water-soluble molecules in the extracellular space, and one or more steps of clarifying and concentrating the suspension in order to isolate the water-soluble molecules, among them phycocyanin. This method is performed at a pH between 5 and 8.5, at room temperature, without drying.

Abstract: The present invention relates to nucleic acids encoding for proteins correlated with the resistance of the Sm1 locus in wheat and uses of these nucleic acids, in particular for conferring or improving resistance to orange wheat blossom midge (OWBM) in a plant.

Abstract: Provided are non-naturally occurring cystine knot peptides (CKPs) that bind to VEGF-A. Additionally, provided are methods of using non-naturally occurring CKPs that bind to VEGF-A, including diagnostic and therapeutic compositions and methods. Non-naturally CKPs that bind low density lipoprotein receptor-related protein 6 (LRP6) are also provided.

Abstract: Provided is a recombinant BPL3 protein having ?-GlcNAc-Sp and a glycan binding specificity, the recombinant BPL3 protein produced by synthesizing a recombinant BPL3 (rBPL3) gene encoding a Bryopsis plumosa lectin (BPL3) protein; preparing a tandem repeat rBPL3 gene including a repeating structure of the rBPL3 gene by tandemly binding the rBPL3 genes through spacers; preparing a recombinant plasmid by inserting the tandem repeat rBPL3 gene into an expression vector; and transforming an expression host by the recombinant plasmid. According to the method, the expression efficiency of the recombinant lectin is maximized and the activity of the manufactured recombinant lectin is enhanced.

Abstract: The invention provides high throughput methods, protein inhibitors, and uses thereof. The invention provides high throughput methods of screening compounds for modulation of protein thermal stability, the method comprising contacting a protein with each of a plurality of test compounds; and (b) measuring the melting transition (Tm) of the protein in the presence of each of the plurality of test compounds, wherein a compound that decreases or increases the apparent Tm by at least 2 standard deviations is identified as a pharmacological protein chaperone.

Abstract: The present disclosure provides hNGAL muteins that bind Ang-2 and can be used in various application including pharmaceutical applications, for example, to inhibit or reduce angiogenesis. The present disclosure also concerns methods of making one or more muteins described herein as well as compositions and combinations comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions and combinations comprising one or more of such muteins.

Abstract: The present disclosure describes a new native peptide designated herein as Dwarf Open Reading Frame, or DWORF. This peptide enhances the apparent activity of the SERCA pump, is positively inotropic and lusitropic, and therefore is provided as a therapeutic agent for disorders characterized by cytosolic calcium overload.

Abstract: The present invention relates to a novel fusion protein comprising the transcription modulation domain of the transcription factor NF-?B subunit p65 and a protein transduction domain and to the use thereof. The fusion protein of the present invention has the effects of inhibiting the transcription of NF-?B and IL-2 by competitive inhibition and inhibiting the LPS-induced secretion of inflammatory cytokines and also inhibiting the production of IL-2, IFN-?, IL-4, IL-17A and IL-10 in splenocytes, and thus is effectively used as a composition for the prevention or treatment of a disease related to NF-?B overactivity.

Abstract: The present invention relates to a fusion polypeptide that inhibits TLR1/2, TLR2/6, TLR7, TLR8 and TLR9 signaling pathways as well as Toll-like receptor 4 (TLR4) and TLR3, and a pharmaceutical composition for preventing or treating TLR pathway mediated diseases. The fusion peptide of the present invention has an excellent effect of inhibiting TLR4 and various TLR pathways and can be effectively used in preventing and treating various TLR pathway mediated diseases caused by the signaling pathways, such as autoimmune diseases, inflammatory diseases and degenerative neurological diseases, by inhibiting the TLR mediated immune responses.

Abstract: The present invention provides a novel peptide compound having an activating action on GIP receptors and use of the peptide compound as a medicament. Specifically, a peptide containing a sequence represented by the formula (I) or a salt thereof and a medicament comprising the same are provided. P1-Tyr-A2-Glu-Gly-Thr-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37-A38-A39-A40-P2?? (I) wherein each symbol is as defined herein.

Abstract: Aspects of the present invention disclose compounds that modulate the aggregation of amyloidogenic proteins or peptides. In some aspects, disclosed compounds modulate the aggregation of disease-associated proteins and natural ?-amyloid peptides. In a preferred embodiment, the compounds can inhibit natural amyloid aggregation. Pharmaceutical compositions comprising the compounds of the embodiments, and diagnostic and treatment methods for diseases (e.g., amyloidogenic diseases) using the compounds, are also disclosed. In addition, there is provided an integrated bacterial platform for the discovery of rescuers of disease-associated protein misfolding.

Abstract: The present invention relates to a method for regulating localization of CCNY protein to synapses, comprising palmitoylation of CCNY protein. Specifically, the present invention relates to a method for regulating targeting of CCNY protein to synapses by regulating addition of a palmitoyl group to cysteine at position 7 and/or 8 on the CCNY protein. Therefore, the palmitoylation of CCNY, a postsynaptic protein known to be implicated in synaptic plasticity and learning and memory, is a critical process for CCNY to be localized in postsynaptic spines, and thus it can be found that CCNY plays an important role in synaptic functions.

Abstract: Disclosed herein are compositions and methods for treating and/or preventing cancer in mammals, and in particular, vaccines that treat and provide protection against tumor growth.

Abstract: Provided are a method for producing a soluble recombinant human-basic fibroblast growth factor (rh-bFGF), a recombinant human-basic fibroblast growth factor (rh-bFGF) obtained by the method, and a mutated nucleic acid molecule encoding the recombinant human-basic fibroblast growth factor (rh-bFGF).

Abstract: The disclosure provides GITRL fusion polypeptide subunits comprising an IgG Fc domain, a trimerization domain, and the receptor binding domain of GITR ligand, where the fusion polypeptide subunits can self-assemble into hexameric proteins. Also provided are methods of making fusion polypeptide subunits and hexameric proteins, and methods of use, e.g., treatment of cancer.

Abstract: The present disclosure provides non-naturally occurring fusion molecules comprising therapeutic cargo moieties, such as IL-22 with a carrier. The disclosure also provides methods and compositions for the production, purification, refolding, formulation, and administration of fusion molecules. Methods and for using the purified molecules to treat and prevent diseases or disorders are also provided herein.

Abstract: The present invention is directed to novel PD-1 targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15R? Fc-fusion protein and a PD-1 antibody fragment-Fc fusion protein. In some embodiments, the PD-1 targeted IL-15/R?-Fc fusion proteins are administered to a patient to treat cancer. In some embodiments, the PD-1 targeted IL-15/R?-Fc fusion proteins are administered in combination with a PD-1 blockade antibody such as nivolumab and/or pembrolizumab. In some embodiments, the PD-1 targeted IL-15/R?-Fc fusion proteins do not compete with a PD-1 blockade antibody such as nivolumab and/or pembrolizumab for antigen binding.

Abstract: The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making the such proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.

Abstract: PYY analogs are disclosed that include modifications that increase half-life when compared to native, human PYY, as well as additional modifications that increase potency and selectivity to the NPY2 receptor. Pharmaceutical compositions also are disclosed that include one or more of the PYY analogs described herein in a pharmaceutically acceptable carrier. Methods of making and using the PYY analogs also are disclosed, especially for treating obesity and obesity-related diseases and disorders such as type II diabetes mellitus.

Abstract: The present invention relates to a novel peptide of a glucagon derivative and a composition for preventing or treating obesity comprising the peptide as an active ingredient. The glucagon derivative according to the present invention shows a more excellent activating effect with regard to both glucagon-like peptide-1 receptors and glucagon receptors compared to native glucagon, and thus can be widely used as an effective agent for treating obesity.

Abstract: A polypeptide comprises an insulin B-chain sequence having the substitutions: Asp at position B10, Ala at position B12, and Glu at position B29, relative to wild type insulin. The polypeptide may additionally comprise a substitution of a halogenated phenylalanine at position B24, such as ortho-fluoro-phenylalanine. Optionally, the polypeptide may additionally comprise a C-terminal dipeptide extension wherein at least one amino acid in the dipeptide contains an acidic side chain, such as Glu-Glu, and/or an N-terminal deletion of one, two or three residues from the B chain. An insulin analogue may comprise any of these polypeptides with an insulin A-chain polypeptide that optionally contains a Glu A8 substitution. The A-chain sequence may be a separate polypeptide or it may be joined to the B-chain polypeptide by a two amino acid linker. The linker may be Trp-Lys or Ala-Lys. The insulin analogue may be used to treat a patient with diabetes mellitus.

Abstract: A single-chain insulin analogue comprises a B-chain insulin polypeptide connected to an A-chain insulin polypeptide by a C-domain polypeptide. The B-chain insulin polypeptide contains a Cysteine substitution at position B4. The A-chain insulin polypeptide contains a Cysteine substitution at position A10. The C-domain polypeptide is 4 to 11 amino acids long. The analogue mitigates the unfavorable activity of this 4th disulfide bridge in conventional two-chain insulin analogues resulting in a duration of insulin signaling similar to that of wild-type insulin. A method of treating a patient with diabetes mellitus comprises the administration of a physiologically effective amount of the protein or a physiologically acceptable salt thereof to a patient. Use of a single-chain insulin analogue of the present invention in an insulin delivery device (such as a pump or pen) or as part of a high-temperature polymer-melt manufacturing process.

Abstract: The present invention relates to a phosphomimetic RAGE protein comprising an amino acid sequence that is at least 90% identical to a native mammalian RAGE isoform or fragment thereof wherein at least one serine present in the cytoplasmatic tail of the mammalian RAGE isoform is replaced by a phosphomimetic structure. The invention further relates to a polynucleotide encoding phosphomimetic RAGE protein and a vector comprising the polynucleotide. Finally, the invention relates to a composition comprising carrier and an active pharmaceutical ingredient, selected from the RAGE protein the vector for use in the treatment or prevention of a disease in a patient, wherein the disease is preferably selected from a disease initiated by impaired DNA repair, a disease initiated by increased DNA damage or a disease initiated by increased senescence.

Abstract: The present disclosure provides variant immunomodulatory polypeptides, and fusion polypeptides comprising the variant immunomodulatory peptides. The present disclosure provides T-cell modulatory multimeric polypeptides, and compositions comprising same, where the T-cell modulatory multimeric polypeptides comprise a variant immunomodulatory polypeptide of the present disclosure. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the T-cell modulatory multimeric polypeptides, and host cells comprising the nucleic acids. The present disclosure provides methods of modulating the activity of a T cell; the methods comprise contacting the T cell with a T-cell modulatory multimeric polypeptide of the present disclosure.

Abstract: Embodiments of the disclosure concern cell therapy methods and compositions utilizing cells expressing at least a chimeric TGF? receptor including the exodomain of a TGF?II receptor and an endodomain that is not from TGF? receptor, thereby converting the negative signal of TGF? for T cell proliferation into a T cell activation signal. In at least certain aspects, cells harboring the chimeric TGF? receptor also harbor one or more chimeric antigen receptors.

Abstract: A method for generating detergent-solubilized G-protein coupled receptors (GPCRs) in powdered form. The powdered GPCRs is storable at temperatures of ?20° C. or lower and for durations of 365 days or longer without substantial loss of functionality of the GPCRs after rehydration as compared to a pre-frozen state. The method can maintain minimal detergent to protein ratio in molar concentrations. The method can further generate GPCRs with specific water or deuterium content as required in certain experiments, such as mass spectrometry, NMR spectroscopy, or quasi-elastic neutron scattering (QENS).

Abstract: The disclosure provides apolipoprotein C-II (apoC-II) mimetic peptides and methods for treating hypertriglyceridemia in a patient with an effective amount of an apoC-II mimetic peptide.

Abstract: An object of the invention is to provide a method for producing a mesenchymal stem cell in which differentiation into an adipocyte is suppressed with a simple step, a mesenchymal stem cell, a method for producing a differentiation-induced cell using the method for producing a mesenchymal stem cell described above, a differentiation-induced cell, and an inhibitor of differentiation into an adipocyte. According to the invention, there is provided a method for producing a mesenchymal stem cell, including: a step of culturing a mesenchymal stem cell in a liquid medium in which a recombinant gelatin having an amino acid sequence derived from a partial amino acid sequence of collagen has been dissolved, wherein differentiation into an adipocyte is suppressed.

Abstract: The present invention provides mutant alpha 1-antitrypsin proteins, pharmaceutical compositions comprising the same, and methods of use thereof in treatment of subjects with an inflammatory disease or disorder.

Abstract: The invention provides modifications within human or humanized single domain antibody fragments (sdAbs) that prevent recognition by pre-existing antibodies, to isolated polypeptides that include these modifications, and to methods and uses thereof.

Abstract: The present invention relates to broadly neutralizing anti-influenza monoclonal antibodies or antigen-binding fragments thereof. The present invention further relates to therapeutic uses of the isolated antibody or the antigen-binding fragment thereof.

Abstract: The present invention features anti-HERV-K monoclonal antibodies or antigen-binding portions thereof. The present invention also features uses of the antibodies for treating HIV infection or HIV-associated conditions or diseases.

Abstract: The present invention relates to broadly neutralizing anti-HIV-1 antibodies and isolated antigens. Also disclosed are related methods and compositions.

Abstract: The present invention provides methods and compositions useful in the field of medicine, and particularly in the treatment of viral infections. More particularly, the invention relates to the use of methods and compositions for the inhibition of human immunodeficiency virus (HIV) transmission.

Abstract: Provided herein are anti-LAP antibodies (e.g., recombinant humanized, chimeric, and human anti-LAP antibodies) or antigen binding fragments thereof which have therapeutically beneficial properties, such as binding specifically to LAP-TGF?1 on cells but not to LAP-TGF?1 in extracellular matrix, as well as compositions including the same. Also provided are uses of these antibodies or antigen binding fragments in therapeutic applications, such as in the treatment of cancer, and diagnostic applications.

Abstract: The present disclosure relates to, inter alia, compositions containing an inhibitor of human complement and use of the compositions in methods for treating or preventing complement-associated disorders. In some embodiments, the inhibitor is chronically administered to patients. In some embodiments, the inhibitor is administered to a patient in an amount and with a frequency to maintain systemic complement inhibition and prevent breakthrough. In some embodiments, the compositions contain an antibody, or antigen-binding fragment thereof, that binds to a human complement component C5 protein or a fragment of the protein such as C5a or C5b.

Abstract: The present invention relates to immunoglobulins that specifically bind Aggrecan and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit the activity of Aggrecan.

Abstract: The present disclosure relates generally to methods of treating a brain injury, preferably a traumatic brain injury, hypoxic brain injury, brain infection, or stroke, comprising administering to a subject an inhibitor of the complement pathway.

Abstract: The invention provides antibody formulations and methods useful for prophylaxis or treatment of synucleinopathies, including Parkinson's disease.

Abstract: The present invention relates to a novel cloning, expression and refolding process for preparing antibody fragments. More particularly, the present invention relates to a cloning, expression and refolding platform for preparing recombinant humanized (rHu) Ranibizumab.

Abstract: A complex comprising a GDF15 polypeptide is described. Methods of treating individuals with a metabolism disorder, such as, glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.

Abstract: Methods of treating genital psoriasis, genital pruritus and genital psoriasis sexual activity impairment with anti-IL17A antibodies, including dose regimens and pharmaceutical formulations of anti-IL17A antibodies for use in the treatment of genital psoriasis, genital pruritus and genital psoriasis sexual activity impairment.

Abstract: Provided is an antibody that binds to human interleukin-2 (hIL-2), and more particularly to an anti-hIL-2 antibody that binds specifically to a particular epitope of hIL-2, thereby inhibiting the binding of the hIL-2 to CD25. The anti-hIL-2 antibody of the subject matter binds specifically to a particular epitope of hIL-2, thereby inhibiting the binding of the hIL-2 to CD25, thereby minimizing expansion of Treg cells. In addition, it stimulates the CD8+ T cells and NK cells that exhibit anti-tumor activity. Thus, the anti-hIL-2 antibody of the present invention is useful as a new anticancer therapeutic agent.